Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells

Figure 5

Interaction of Smac/DIABLO with IAPs. MDA-MB-468 cells were transiently transfected with plasmids expressing Smac/DIABLO full length (MDA-MB-468/Smac) or neo (MDA-MB-468/neo) gene for 24 h, and treated with doxorubicin (100 nM), paclitaxel (100 nM), tamoxifen (100 nm) or TRAIL (75 nM) for 24 h. Cells were harvested, and immunoprecipitated with anti-Smac antibody. Immunoprecipitated complexes were subjected to SDS-PAGE and immunoblotted with anti-cIAP1, anti-cIAP2 or anti-XIAP antibody. Anti-β-actin antibody was used as a control in whole cell lysate.

Back to article page